Freyja Healthcare, LLC announced today that the U.S. Food and Drug Administration has granted 510(k) clearance for VereSee™, its second-generation Mini Laparoscope with VisualEntry™ System. The clearance marks a significant step for the company in its mission to bring visualization to the earliest stages of minimally invasive surgery.
VereSee combines a miniature 2mm laparoscope with Freyja's VisualEntry System, allowing surgeons to see anatomy during the entry process—a critical step that traditionally is performed without direct visualization. This innovative approach may reduce risks associated with blind entry and enhance surgical precision.
“FDA clearance of VereSee is an incredibly important milestone for Freyja Healthcare,” said Mike MacKinnon, CEO. “We believe surgeons should have the ability to see when it matters most. VereSee brings visualization to the very beginning of the procedure while also providing the functionality of a miniature laparoscope, which may enable surgeons to avoid opening an additional laparoscope for certain procedures.”
The system is designed to fit naturally into the laparoscopic workflow. It pairs single-use entry components with reusable visualization technology, supporting a practical healthcare economic model. Once access is achieved, surgeons may continue to use the same miniature laparoscope for visualization, potentially eliminating the need for additional instruments.
VereSee was reviewed under the FDA's 510(k) premarket notification pathway and is classified as a Class II Endoscope and Accessories device. This clearance allows Freyja to begin commercial introduction in hospitals and ambulatory surgical centers.
Jon I. Einarsson, MD, founder of Freyja Healthcare, emphasized the broader implications: “VereSee represents more than a new method of laparoscopic entry. It is a miniature laparoscopic visualization platform that gives surgeons the opportunity to see anatomy from the moment of entry. We believe that has the potential to fundamentally change how surgeons think about access, while continuing to advance the miniaturization of laparoscopic visualization and scope functionality.”
The importance of this clearance extends beyond Freyja. Laparoscopic procedures, which are performed millions of times annually, rely on safe entry to avoid complications. By providing direct visualization during entry, VereSee could improve patient safety and outcomes. It also aligns with the trend toward miniaturization in surgery, potentially reducing tissue trauma and improving recovery times.
For healthcare systems, the reusable visualization technology may offer cost efficiencies over single-use scopes. For surgeons, it provides enhanced situational awareness from the start of the procedure. For patients, it may mean fewer risks and better outcomes.
Freyja Healthcare, based in Framingham, MA, focuses on developing innovative solutions for minimally invasive surgery and women's health. The company says it aims to address meaningful unmet needs for physicians, healthcare systems, and patients. With this clearance, Freyja is poised to introduce a technology that could reshape laparoscopic practice.
